Studying the pathophysiology of coronavirus disease 2019 – a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19)
Authors:
- Florian KurthFKFlorian Kurth
- Charlotte ThibeaultCTCharlotte Thibeault
- Victor M. CormanVCVictor M. Corman
- Holger Mueller-RedetzkyHMHolger Mueller-Redetzky
- Mirja MittermaierMMMirja Mittermaier
- Christoph Ruwwe-GloesenkampCRChristoph Ruwwe-Gloesenkamp
- Alexander KrannichAKAlexander Krannich
- Sein SchmidtSSSein Schmidt
- Lucie KretzlerLKLucie Kretzler
- Chantip Dang-HeineCDChantip Dang-Heine
- Matthias RoseMRMatthias Rose
Preprint
Abstract
Purpose: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide causing a global health emergency. Pa-COVID-19 aims to provide comprehensive data on clinical course, pathophysiology, immunology and outcome of COVID-19, in order to identify prognostic biomarkers, clinical scores, and therapeutic targets for improved clinical management and preventive interventions. Methods: Pa-COVID-19 is a prospective observational cohort study of patients with confirmed SARS-CoV-2 infection treated at Charité - Universitätsmedizin Berlin. We collect data on epidemiology, demography, medical history, symptoms, clinical course, pathogen testing and treatment. Systematic, serial blood sampling will allow deep molecular and immunological phenotyping, transcriptomic profiling, and comprehensive biobanking. Longitudinal data and sample collection during hospitalization will be supplemented by long-term follow-up. Results: Outcome measures include the WHO clinical ordinal scale on day 15 and clinical, functional and health-related quality of life assessments at discharge and during follow-up. We developed a scalable dataset to ( i ) suit national standards of care ( ii ) facilitate comprehensive data collection in medical care facilities with varying resources and ( iii ) allow for rapid implementation of interventional trials based on the standardized study design and data collection. We propose this scalable protocol as blueprint for harmonized data collection and deep phenotyping in COVID-19 in Germany. Conclusion: We established a basic platform for harmonized, scalable data collection, pathophysiological analysis, and deep phenotyping of COVID-19, which enables rapid generation of evidence for improved medical care and identification of candidate therapeutic and preventive strategies. The electronic database accredited for interventional trials allows fast trial implementation for candidate therapeutic agents.Keywords
All Related Versions
- Published version: Infection, 48 (4), 619.
This publication has 25 references indexed in Scilit:
- Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected PneumoniaNew England Journal of Medicine, 2020
- Transmission of 2019-nCoV Infection from an Asymptomatic Contact in GermanyNew England Journal of Medicine, 2020
- Importation and Human-to-Human Transmission of a Novel Coronavirus in VietnamNew England Journal of Medicine, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- The Middle East Respiratory Syndrome (MERS)Infectious Disease Clinics of North America, 2019
- Middle East Respiratory SyndromeNew England Journal of Medicine, 2017
- PROGRESS – prospective observational study on hospitalized community acquired pneumoniaBMC Pulmonary Medicine, 2016
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi ArabiaNew England Journal of Medicine, 2012
- Severe acute respiratory syndromeNature Medicine, 2004
- CAPNETZ?Community-Acquired Pneumonia Competence NetworkInfection, 2004